Journals infiltrated with ‘copycat’ papers that can be written by AI

A recent preprint highlights a growing concern that AI tools, including ChatGPT and Gemini, are being used to generate 'copycat' research papers that successfully bypass standard plagiarism checks. Researchers identified over 400 such articles published in 112 journals over the past 4.5 years, often created by subtly re-analyzing public health datasets. This trend risks flooding scientific literature with low-quality, redundant studies, potentially undermining research integrity and complicating due diligence for R&D investments in sectors like pharmaceuticals and biotechnology.

Analysis

A recent preprint study reveals a significant emerging risk to the integrity of scientific literature, with direct implications for R&D-intensive sectors. Researchers have identified over 400 'copycat' academic papers published in 112 journals, which appear to be generated by large language models like OpenAI's ChatGPT and Alphabet's Gemini (GOOGL). These AI tools are being used to rewrite existing research, often leveraging large, open-access health databases like NHANES, to create redundant studies that successfully bypass standard plagiarism-detection software. This development poses a systemic threat by potentially flooding the biomedical field with low-quality, derivative work, thereby complicating due diligence for investors in pharmaceuticals and biotechnology who rely on published studies to validate therapeutic pipelines. The negative sentiment (-0.6 for GOOGL) reflects the reputational risk for AI developers whose tools are being exploited. However, the low market impact score of 0.3 suggests that, for now, this is viewed as a longer-term regulatory and ethical issue rather than an immediate driver of market volatility.

Key Decisions for Investors

• Investors in the healthcare and biotech sectors should incorporate heightened scrutiny into their due diligence process, verifying the novelty and originality of scientific papers that support a company's R&D claims.
• For investors in Alphabet (GOOGL), this misuse of its Gemini AI represents a growing reputational and regulatory risk that should be monitored, as it could lead to calls for stricter controls on AI-generated content.
• Portfolio managers should be cautious of using the volume of published research as a key performance indicator for innovation, as its value is being diluted by the potential for mass-produced, low-value synthetic papers.